Xenon’s lead in-house drug flops in a mid-stage test and stock plunges lower
Xenon Pharmaceuticals has another setback to report.
Twenty months after its drug TV-45070 failed a mid-stage osteoarthritis study in Teva’s hands, the Canadian biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
